The efficacy of third or fourth line H. pylori eradication therapy with refabutin-amoxicillin-vonaprazan 7day regimen

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031180362

Enrollment

100

Registered

2019-03-18

Start date

2016-03-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

vonoprazan 40mg, b.i.d., amoxicillin 2.0g, q.i.d., rifabutin 300mg, o.d. 7 days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: H. pylori-positve patients after the 2nd line H. pylori eradication therapy with informed consent

Exclusion criteria

Exclusion criteria: 1. Patients with allergy for rifamycins 2. Patients with past histry of tuberculosis or nontuberculous mycobacterial infection 3. Patients with allergy for PPIs 4. Patients with allergy for penicillin 5. Patients with severe liver injury and/or severe renal damage 6. Pregnancy or possible pregnancy 7. Patients who are taking voriconazole 8. Patients with uveitis 9. Patients who were recognized as inappropriate for entry

Design outcomes

Primary

Measure	Time frame
The efficacy of eradication treatment	—

Secondary

Measure	Time frame
1) MIC of AMPC and RFB 2) rpoB mutation analysis of H.pylori	—

Contacts

Public ContactKenro Hirata

Keio University Hospital

Kenro916@gmail.com+81-3-5363-3790

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026